Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125595683 | 12559568 | 3 | F | 2013 | 20160810 | 20160715 | 20160812 | EXP | PHHY2016KR002841 | NOVARTIS | 63.63 | YR | F | Y | 0.00000 | 20160812 | CN | COUNTRY NOT SPECIFIED | KR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125595683 | 12559568 | 1 | SS | GLIVEC | IMATINIB MESYLATE | 1 | Oral | 400 MG, QD | Y | 0 | 400 | MG | TABLET | QD | |||||
| 125595683 | 12559568 | 2 | PS | TASIGNA | NILOTINIB | 1 | Oral | 400 MG, BID | 22068 | 400 | MG | CAPSULE | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125595683 | 12559568 | 1 | Chronic myeloid leukaemia |
| 125595683 | 12559568 | 2 | Chronic myeloid leukaemia |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125595683 | 12559568 | Alopecia | |
| 125595683 | 12559568 | Anaemia | |
| 125595683 | 12559568 | Hyperlipidaemia | |
| 125595683 | 12559568 | Hypothyroidism |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125595683 | 12559568 | 1 | 20110621 | 0 | ||
| 125595683 | 12559568 | 2 | 201205 | 0 |